Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 13/20 | 0.55 |
| ▸ | KRAS | P01116 | 12/20 | 0.55 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.51 |
| ▸ | TCF7L2 | Q9NQB0 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | GRK6 | P43250 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490331 | 1.00 | SOS1 (0.55) | SOS1KRASCTNNB1TCF7L2EGFR | |
| SCHEMBL29490290 | 0.89 | CTNNB1 (0.52) | SOS1KRASCTNNB1TCF7L2EGFR | |
| SCHEMBL22862498 | 0.89 | CTNNB1 (0.52) | SOS1KRASCTNNB1TCF7L2EGFR | |
| SCHEMBL22862605 | 0.83 | CTNNB1 (0.45) | SOS1KRASCTNNB1TCF7L2EGFR | |
| SCHEMBL29490271 | 0.83 | CTNNB1 (0.45) | SOS1KRASCTNNB1TCF7L2EGFR | |
| SCHEMBL22862533 | 0.82 | KRAS (0.58) | SOS1KRASCTNNB1TCF7L2EGFR | |
| SCHEMBL29490266 | 0.82 | KRAS (0.58) | SOS1KRASCTNNB1TCF7L2EGFR | |
| SCHEMBL38653314 | 0.79 | KRAS (0.42) | SOS1KRASCTNNB1TCF7L2EGFR | |
| SCHEMBL22862718 | 0.79 | KRAS (0.42) | SOS1KRASCTNNB1TCF7L2EGFR | |
| SCHEMBL20509925 | 0.78 | SOS1 (0.50) | SOS1KRASEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
| WO-2021002986-A2 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | BAX, TMBIM6, BCL2 | SOS1 1949/4885KRAS 77/4885CTNNB1 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.